Close Menu

NEW YORK – Belgium-based Biocartis has signed a master collaboration agreement with AstraZeneca, expanding an existing partnership that aims to demonstrate how Biocartis' Idylla platform can reduce the complexity and long turnaround time of biomarker testing for lung cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.